GSK India's net profit jumps 35% in Q4FY25, led by growth of respiratory and vaccine portfolios

GSK India

GlaxoSmithKline Pharmaceuticals, the Indian arm of UK-based GSK, reported a 35% year-on-year jump in consolidated net profit for the fourth quarter of FY25, driven by robust growth in its respiratory and vaccine portfolios. Net profit for the quarter ended March 31, 2025, rose to Rs 262.9 crore, while revenue grew 4.8% to Rs 974.4 crore.

The EBITDA grew 30% YoY in Q4FY25 to Rs 331 crore on standalone basis, and the EBITDA margins expanded 620 basis to 34% led by softening of raw material prices; improved productivity and cost efficiencies.

The company also emphasized its focus on operational efficiency, with SG&A expenses as a percentage of sales down 4.2% YoY in Q4, and field productivity improving by 9%.

For the full fiscal year, consolidated revenue rose 8.6% to Rs 3,749 crore, and net profit surged 57% to Rs 927.6 crore. The board recommended a final dividend of Rs 42 per share, up from Rs 32 last year. The full year EBITDA improved by around 30% to Rs 1169 crore and EBITDA margins expanded by 500 basis points to 31%.

“Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced HCP engagement, and rapid digital acceleration,” said Bhushan Akshikar, Managing Director of GSK Pharmaceuticals India. “Key brands like Augmentin, Calpol, Ceftum, T-Bact, and Trelegy have played a significant role in driving growth.”

Looking ahead, GSK plans to launch two oncology assets in India - Zejula (Niraparib) - a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab) an immunotherapy for second-line treatment of endometrial cancer.

“In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,” Akshikar added.